Emergent BioSolutions appoints DeGolyer and Fowler to board, adopts inducement plan

Emergent BioSolutions Inc.

Donald DeGolyer and Neal Fowler appointed Class III directors effective Oct 1, 2023; terms expire at 2024 annual meeting.
Both are independent; DeGolyer on Compensation Committee, Fowler on Audit and Finance Committee.
Each receives initial RSU grant valued at $375,000, vesting in three equal annual installments.
Board adopted Inducement Plan reserving 5 million shares for equity grants to new hires.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Neal Fowler

Class III Director

EBS · Emergent BioSolutions Inc.

Effective: 2023-10-01
Filed: October 2, 2023, 7:59 PM ET

On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023

Appointed

Donald DeGolyer

Class III Director

EBS · Emergent BioSolutions Inc.

Effective: 2023-10-01
Filed: October 2, 2023, 7:59 PM ET

On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neal Fowler was appointed as Class III Director at Emergent BioSolutions Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Donald DeGolyer was appointed as Class III Director at Emergent BioSolutions Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.